Is UNII-DPT0O3T46P Safe in Breastfeeding
Question
I am a breastfeeding mother and i want to know if it is safe to use UNII-DPT0O3T46P? Is UNII-DPT0O3T46P safe for nursing mother and child? Does UNII-DPT0O3T46P extracts into breast milk? Does UNII-DPT0O3T46P has any long term or short term side effects on infants? Can UNII-DPT0O3T46P influence milk supply or can UNII-DPT0O3T46P decrease milk supply in lactating mothers?
Answer by DrLact: About UNII-DPT0O3T46P usage in lactation
No information is available on the clinical use of UNII-DPT0O3T46P during breastfeeding. Because UNII-DPT0O3T46P is a large protein molecule with a molecular weight of about 149,000, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Until more data become available, UNII-DPT0O3T46P should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant. The manufacturer recommends that breastfeeding be discontinued during UNII-DPT0O3T46P therapy and for 4 months after the last dose.
Alternate Drugs
Daclizumab(Low Risk)
Alemtuzumab(Low Risk)
Tocilizumab(Low Risk)
Adalimumab(Safe)
Erlotinib(Unsafe)
Fluorouracil(Dangerous)
Thioguanine(Dangerous)
Vincristine(Dangerous)
Alemtuzumab(Low Risk)
Tamoxifen(Dangerous)
Rituximab(Low Risk)
Mitoxantrone(Dangerous)
Bevacizumab(Low Risk)
Mercaptopurine(Safe)
Letrozole(Dangerous)
Exemestane(Dangerous)
Dactinomycin(Dangerous)
Hydroxyurea(Low Risk)
Trastuzumab(Unsafe)
Dasatinib(Unsafe)
Etoposide(Dangerous)
Nilotinib(Unsafe)
Doxorubicin(Dangerous)
Cyclophosphamide(Dangerous)
Imatinib(Unsafe)
Cisplatin(Unsafe)
Nivolumab(Unsafe)
Docetaxel(Dangerous)
Busulfan(Dangerous)
Vinblastine(Dangerous)
Pazopanib(Unsafe)
Azelaic Acid(Safe)
Gemcitabine(Dangerous)
Ipilimumab(Unsafe)
Bleomycin(Dangerous)
Cetuximab(Unsafe)
Vinorelbine(Dangerous)
Carboplatin(Dangerous)
Dacarbazine(Dangerous)
Paclitaxel(Dangerous)
Cladribine(Dangerous)
Nivolumab(Unsafe)
Ipilimumab(Unsafe)
Nivolumab(Unsafe)
Ipilimumab(Unsafe)
Glatiramer(Low Risk)
Nivolumab(Unsafe)
Ipilimumab(Unsafe)